NCT04186403View on ClinicalTrials.gov

Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

September 22, 2021

Study Completion Date

September 22, 2021

Conditions
Borderline Personality Disorder
Interventions
DRUG

Brexpiprazole

Administered as tablets.

Trial Locations (1)

10012

For additional information regarding sites, contact 844-687-8522, New York

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04186403 - Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD) | Biotech Hunter | Biotech Hunter